« Return to News | R&D Trends

U.K. groups unveil innovative $80 million cancer fund

Friday, March 30, 2012 09:22 AM

Cancer Research Technology (CRT), Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create an $80 million investment fund to bridge the funding gap in the U.K. between cancer drug discovery and early development.

The CRT Pioneer Fund will take potential cancer drugs from discovery through to the beginning of phase II clinical trials. CRT and the EIF will make equal contributions to the CRT Pioneer Fund.

Dr. Keith Blundy, CEO of Cancer Research Technology, said, "The creation of this landmark fund addresses the problem of funding the development gap which is restraining cancer drug development in the U.K. Investment from industry has moved away from early stage discovery and there's less funding for small biotechnology firms who previously helped bridge the gap between academia and pharmaceutical companies.”

"This important investment means we can take forward the most innovative approaches using our in-house drug discovery and development capabilities, to progress promising treatments from the lab all the way to clinical trials, translating our world-class scientific research into new treatments more quickly."

At least two thirds of the fund will be used to develop the most exciting scientific discoveries made by Cancer Research U.K. scientists. The remaining projects may come from other academic groups or industry in the U.K. CRT will re-invest its share of any profits derived from the fund in Cancer Research U.K.'s research.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.